Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion

Trial Profile

Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Docetaxel (Primary) ; Plinabulin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DUBLIN-3
  • Sponsors BeyondSpring Pharmaceuticals
  • Most Recent Events

    • 14 Dec 2017 Interim anti-cancer efficacy data is expected in mid-2018, according to a BeyondSpring Pharmaceuticals media release.
    • 14 Dec 2017 Results published in the BeyondSpring Pharmaceuticals Media Release
    • 09 Nov 2017 According to a BeyondSpring Pharmaceuticals media release, interim data from this trial are expected in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top